Dr. Laurence Chen is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm’s patents and innovations practice. His technical expertise spans a variety of fields including biological engineering, gene editing, cancer immunotherapy, and multi-omic technologies.
Prior to joining the firm, Laurence completed his doctorate degree in chemical engineering at the University of California, Los Angeles. His doctoral research leveraged synthetic biology, protein engineering, cell engineering, and multi-omics in developing CAR-T cells for next-generation cancer immunotherapies. His graduate work has resulted in multiple scientific publications and he is also a co-inventor on multiple patent applications.
Dr. Laurence Chen is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm’s patents and innovations practice. His technical expertise spans a variety of fields including biological engineering, gene editing, cancer immunotherapy, and multi-omic technologies.
Prior to joining the firm, Laurence completed his doctorate degree in chemical engineering at the University of California, Los Angeles. His doctoral research leveraged synthetic biology, protein engineering, cell engineering, and multi-omics in developing CAR-T cells for next-generation cancer immunotherapies. His graduate work has resulted in multiple scientific publications and he is also a co-inventor on multiple patent applications.
- Ph.D., Chemical Engineering, University of California, Los Angeles, 2022
- B.S., Bioengineering: Biotechnology, University of California, San Diego, 2016
- U.S. Patent and Trademark Office
- Ph.D., Chemical Engineering, University of California, Los Angeles, 2022
- B.S., Bioengineering: Biotechnology, University of California, San Diego, 2016
- U.S. Patent and Trademark Office
Select Publications
- Co-lead author with X. Chen and Y.Y. Chen, “Rational protein design yields a CD20 CAR with superior antitumor efficacy compared to CD19 CAR,” Cancer Immunology Research, 2022
- Co-author with A. Lakhani, Y.Y. Chen, and J.O. Park, “Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation,” Nature Metabolism, 2024
- Co-lead author with A.J. Hou and Y.Y. Chen, “Navigating CAR-T cells through the solid-tumour microenvironment,” Nature Reviews Drug Discovery, 2021
- Lead author with Y.Y. Chen, “Bacteria recycle tumour waste to fuel immune cells,” Nature (News & Views), 2021
- Lead author with Y.Y. Chen, “Outsmarting and outmuscling cancer cells with synthetic and systems immunology,” Current Opinion in Biotechnology, 2019
Select Publications
- Co-lead author with X. Chen and Y.Y. Chen, “Rational protein design yields a CD20 CAR with superior antitumor efficacy compared to CD19 CAR,” Cancer Immunology Research, 2022
- Co-author with A. Lakhani, Y.Y. Chen, and J.O. Park, “Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation,” Nature Metabolism, 2024
- Co-lead author with A.J. Hou and Y.Y. Chen, “Navigating CAR-T cells through the solid-tumour microenvironment,” Nature Reviews Drug Discovery, 2021
- Lead author with Y.Y. Chen, “Bacteria recycle tumour waste to fuel immune cells,” Nature (News & Views), 2021
- Lead author with Y.Y. Chen, “Outsmarting and outmuscling cancer cells with synthetic and systems immunology,” Current Opinion in Biotechnology, 2019
- Privacy Policy
- Terms of Use
- Accessibility